Edoxaban Exposure in Patients With Atrial Fibrillation and Estimated Creatinine Clearance Exceeding 100 mL/min

Edoxaban 60 mg is approved for stroke prevention in patients with atrial fibrillation (AF) not fulfilling any dose‐reduction criteria. As edoxaban is partially renally cleared (≈50%), this study compared pharmacokinetics (PK) and pharmacodynamics of edoxaban 60 mg once daily with edoxaban 75 mg once...

Descripción completa

Detalles Bibliográficos
Autores principales: Yin, Ophelia, Kakkar, Tarundeep, Duggal, Anil, Kotsuma, Masakatsu, Shi, Minggao, Lanz, Hans, Grosso, Michael A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9299591/
https://www.ncbi.nlm.nih.gov/pubmed/34877813
http://dx.doi.org/10.1002/cpdd.1050

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9299591/
https://www.ncbi.nlm.nih.gov/pubmed/34877813
http://dx.doi.org/10.1002/cpdd.1050

Ejemplares similares